FACULTY
Yussef Bennani
ASSISTANT PROFESSOR - CLINICAL
Med-Infectious disease
- ybenn1@lsuhsc.edu
- Medicine
Academic Office:
LSUHSC School of Medicine
1542 Tulane Ave. 4th floor
New Orleans, LA 70112
Clinical Office:
University Medical Center, HIV Outpatient Program Clinic
2000 Canal Street
New Orleans, LA 70112
Bio
Dr. Bennani completed his medical degree in 2011 from Tulane University. He remained at Tulane to complete his residency in internal medicine and a fellowship in infectious diseases, as well as additional training in tropical medicine. After completing his medical training, he joined the LSU Infectious Diseases section with a focus on HIV medicine and the management of hepatitis C. His primary area of interest is the intersection of HIV and co-morbid chronic disease including malignancy, cardiovascular and renal disease. He is also interested in the management and public health aspects of the hepatitis C epidemic, particularly in relation to ongoing IV drug use. In addition to seeing patients in clinic, he oversees the HIV clinical trials team, and attends on the infectious diseases service at University Medical Center New Orleans, where he was recognized as Best Physician Consultant in 2019. He has also been actively involved in clinical trials at UMCNO during the COVID-19 pandemic. Prior to his career in medicine, Dr. Bennani worked as an epidemiologist with the New York City Department of Health and Mental Hygiene, with an emphasis on the epidemiology of incident HIV infections, transmission of resistant strains of HIV, and work to better characterize the HIV epidemic in persons with infrequent healthcare contact. Dr. Bennani is originally a native of Lexington, Massachusetts.
Education
Undergraduate:
1998 - B.A., Biopsychology
Vassar College
Poughkeepsie, NY
Graduate:
2001 - Master of Public Health, International Health and Development/Epidemiology
Tulane University School of Public Health and Tropical Medicine
New Orleans, Louisiana
Medical:
2011 - M.D.
Tulane University School of Medicine
New Orleans, Louisiana
Residency:
2011-2014 - Internal Medicine
Tulane University School of Medicine
New Orleans, Louisiana
Fellowship:
2014-2016 - Infectious Diseases
Tulane University School of Medicine
New Orleans, Louisiana
Other:
2016 - Certificate in Tropical Medicine and Travelers’ Health
Tulane University School of Public Health and Tropical Medicine
New Orleans, Louisiana
Affiliated Hospitals & Clinics
- University Medical Center
- University Medical Center, HIV Outpatient Program Clinic
Publications
1.Nash D, Ramaswamy C, Manning S. [also Jones L, Figueroa D, Ly S, Shum R, Singh T,
Forlenza S, Sackoff J, Torian L, Pfeiffer M, Katyal M, Bennani Y, Quintyne R, Bramble G, Castellan R, Davis W, Evans R, Gibbs V, Lashley S, McNamee
P, Pruitt G, Rosas P, Smith W, Storck C, Thompson D, Torbert A, Peter Vs, Brooks A,
Mapson C, Thomas P, Dicker R et al. Implementation of Named HIV Reporting — New York
City, 2001. MMWR January 2, 2004; 52(51):1248-1252.
2. Nash D, Bennani Y, Ramaswamy C, Torian L. Estimates of HIV incidence among persons testing for HIV
using the sensitive/less sensitive enzyme immunoassay, New York City, 2001. J Acquir
Immune Defic Syndr. 2005; 39(1):102-11.
3. Hall HI, Song R, Rhodes P, Prejean J, An Q, Lee LM, Karon J, Brookmeyer R, Kaplan
EH, McKenna MT, Janssen RS; HIV Incidence Surveillance Group*. Estimation of HIV
incidence in the United States. JAMA. 2008; 300(5):520-9. (* as NYC investigator in
HIV Incidence Surveillance Group)
4. Begier E, Bennani Y, Forgione L, Punsalang A, Hanna D, Herrera J, Torian L, Gbur M, Sepkowitz KA, Parvez
F. Undiagnosed HIV Infection Among New York City Jail Entrants, 2006: Results of a
Blinded Serosurvey. J Acquir Immune Defic Syndr. 2010; 54(1):93-101.
5. Kerker BD, Bainbridge J, Kennedy J, Bennani Y, Agerton TB, Marder D, Thorpe L. A Population-Based Assessment of the Health of
Homeless Families in New York City, 2001-2003. Am J Public Health. 2011; 101(3):
546-53.
6. Azhar A, Connell HE, Haas C, Surla J, Reed D, Kamboj S, Love GL, Bennani Y. Cutaneous Leishmaniasis in Louisiana. One-year follow-up. Case Report and Literature
Review. World J Infect Dis. 2021; 11(1):19-26.
Research
Title: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching
from a Regimen of Dolutegravir and ABC/3TC, or a Fixed Dose Combination (FDC) of ABC/DTG/3TC
to a FDC of GS-9883/F/TAF in HIV-1 Infected Subjects who are Virologically Suppressed
Sponsor: Gilead Sciences, Inc.
Role: Principal investigator
Dates: 2017 – 2020
Title: A Phase 3, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Switching
from Regimens Consisting of Boosted Atazanavir or Darunavir plus either Emtricitabine/Tenofovir
or Abacavir/Lamivudine to GS-9883/Emtricitabine/Tenofovir Alafenamide in Virologically
Suppressed HIV-1 Infected Adults
Sponsor: Gilead Sciences, Inc.
Role: Principal investigator
Dates: 2017 – 2020
Title: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of
GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine
in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults.
Sponsor: Gilead Sciences, Inc.
Role: Principal investigator
Dates: 2017 – 2020
Title: A Phase 3b, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Infected
Subjects who are Virologically Suppressed on Regimens containing ABC/3TC.
Sponsor: Gilead Sciences, Inc.
Role: Principal investigator
Dates: 2017 – 2020
Title: Phase I Study of MK-3475 (Pembrolizumab) in Patients with Human Immunodeficiency
Virus (HIV) and Relapsed/Refractory or Disseminated Malignant Neoplasm
Sponsor: National Cancer Institute (NCI)
Role: Co- Investigator
Dates: 2017-present
Title: Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two
Nucleos(t)ide Reverse Transcriptase Inhibitors (NRTI) plus a Third Agent to a Fixed
Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF),
in Virologically-Suppressed, HIV-1 Infected African American Subjects
Sponsor: Gilead Sciences, Inc.
Role: Principal investigator
Dates: 2018-2020
Title: Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two
Nucleos(t)ide Reverse Transcriptase Inhibitors (NRTI) plus a Third Agent to a Fixed
Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF),
in Virologically-Suppressed, HIV-1 Infected African American Subjects
Sponsor: Gilead Sciences, Inc.
Role: Principal investigator
Dates: 2018-2020
Title: Adaptive Phase 2, Randomized, Open-Label, Controlled Study to Evaluate the Efficacy
and Safety of Sirukumab in Hospitalized Coronavirus Disease (COVID-19) Participants
with Severe Hypoxia
Sponsor: Janssen Research and Development, L.L.C.
Role: Co-investigator
Dates: 2020-20201
Title: Treatment in Patients with Suspected or Confirmed COVID-19 with Moderate or Severe
disease: A Randomized Clinical Trial
Sponsor: University Medical Center New Orleans
Role: Co-investigator
Dates: 2020
Title: Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and
Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral
Agents in People Living with HIV.
Sponsor: Gilead Sciences, Inc.
Role: Principal investigator
Dates: 2019 - 2020
Title: Phase IIIb, Randomized, Multicenter, Active-controlled, Parallel group, Non-inferiority,
Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to
Long-acting Cabotegravir Plus Long-acting Rilpivirine administered every two months
from a Bictegravir/emtricitabine/tenofovir alfenamide Single Tablet Regimen in HIV-1
Infected Adults who are Virologically Suppressed
Sponsor: ViiV Healthcare/GlaxoSmithKline
Role: Principal investigator
Dates: 2020 - 2021